In contrast, SAP is the initial manifestation of ischemic heart disease in one half of patients and becomes a recurrent symptom in survivors of ACS that is generally due to one or more significant obstructive but more stable lesions in coronary arteries [ 1- 4].
Fox and coworkers [ 14] exploited this effect of the drug in more than 10,000 patients with stable coronary artery disease and left ventricular ejection fraction less than 40% recruited over 2 years.
More than half of patients with stable coronary artery disease are now implanted with stents without even trying drug treatment, Dr. Brown said.
In populations with a higher pre-test probability for heart failure, as patients with diabetes, hypertension and stable coronary artery disease, screening would presumably be more cost-effective, but evidence for the use in this setting is still lacking.
Most interventional cardiologists (89%, n=120) each performed percutaneous coronary intervention on 1-14 patients with stable coronary artery disease, whereas 15 (11%) did so on more than 15 patients each (table 1).
28): Commenting on his own research study, Dr. David Brown suggests that interventional cardiologists perform angioplasty procedures, with or without stents, in patients with stable coronary artery disease because of pressure from hospitals to generate more revenue.
19 A more contemporary study found that 82% and 88% of 153 patients with stable coronary artery disease undergoing elective coronary angiography at one site believed that percutaneous coronary intervention would decrease their risk of fatal and future myocardial infarction, respectively.
Uptake rates of statins and angiotensin converting enzyme inhibitors or angiotensin receptor blockers more than doubled between 2000 and 2010 for secondary prevention and the management of stable coronary artery disease (table 5).
More than 11 000 patients with oral clopidogrel loading, including the whole clinical PCI spectrum (56% stable coronary artery disease (CAD), 26% non-ST-elevation acute coronary syndrome (NSTE-ACS), 18% ST-elevation myocardial infarction (STEMI)), were preinterventionally randomised to receive an intravenous bolus and infusion of cangrelor, a fast acting reversible ADP receptor blocker.
